摘要
目的:探讨CD7和CD56共表达免疫表型对急性髓系白血病(acute myelocytic leukemia,AML)侵袭性的影响。方法:采用多色流式细胞术检测AML患者免疫表型,对6例CD7^+CD56^+AML患者和6例CD7^-CD56^-AML患者进行临床资料比较和无病生存(disease-free survival,DFS)率随访。结果:CD7^+CD56^+AML在M_0+M_1分型中的分布比例、外周血血红蛋白、骨髓原始细胞比例、中枢系统浸润率均高于CD7^-CD56^-AML,差异具有显著统计学意义(P<0.01或P<0.05);但平均无病生存期低于CD7^-CD56^-AML,差异具有显著统计学意义(P<0.01)。结论:AML中检出CD7、CD56的共表达的免疫表型意味着预后较差,需加强巩固治疗和中枢系统微小残留病灶监测。
Objective To investigate the effect of co-expression of CD7 and CD56 to invasiveness of acute myelocytic leukemia （AML）. Methods The immunophenotype of AML was detected by flow cytometry in 6 patients with CD7^＋CD56^＋AML in 6 patients with CD7^-CD56^- AML. Their clinical datas and disease-free survival （DFS） rates were compared. Result The distribution rate in FAB-M0 ＋ M1 , hemoglobin（Hb） in peripheral blood（PB） ,percent of blast cells in bone marrow（ BM）, invasion rate of central system of patients with CD7^＋CD56^＋AML were significantly higher than patients with CD7 - CD56 - AML（ P 〈 0.01 or P 〈 0.05 ）. The DFS rate of patients with CD7 ~ CD56 ~ AML was significantly lower than patients with CD7^- CD56^- AML （P 〈 0.01 ）. Conclusion The co-expression of CD7 and CD56 indicates a poor prognosis. Enhanced treatment and microresidual disease detection should be per- formed.
出处
《放射免疫学杂志》
CAS
2012年第2期197-199,共3页
Journal of Radioimmanology
